 |
인쇄하기
취소
|
Yuhan's Revanex has fared well in anti-ulcerant market
With the renormalized distribution last week, Yuhan's novel proton inhibitor Revanex (revaprazan) is expanding its share of the domestic anti-ulcerant market.
Revanex' sales have exceeded the 10 billion won mark in just 12 months after Yuhan launched the drug last year. The company says Revanex is expected to reach 20 billion won in sales this year.
In the similar vein, the sales of Dong-...
Revanex' sales have exceeded the 10 billion won mark in just 12 months after Yuhan launched the drug last year. The company says Revanex is expected to reach 20 billion won in sales this year.
In the similar vein, the sales of Dong-...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.